Pharmaceutical

Dragonfly and Gilead enter partnership for cancer therapy

Dragonfly Therapeutics has entered a clinical collaboration with Gilead Sciences to assess DF1001 plus Trodelvy for cancer indications.

Feb 16, 2024 - 18:00
Dragonfly and Gilead enter partnership for cancer therapy
Dragonfly Therapeutics has entered a clinical collaboration with Gilead Sciences to assess DF1001 plus Trodelvy for cancer indications.
Read the original article

Tags:

Previous Article

Regeneron and Sanofi’s Dupixent bags fifth drug label in Japan

Next Article

FDA grants orphan drug status to Ionis’ olezarsen for FCS treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: South Africa faces court hearing over opaque Covid-19 vaccine contracts

STAT+: South Africa faces court hearing over opaque Cov...

Jul 26, 2023

‘We fail people’: New data on disparities in Medicaid access to opioid addiction treatment

‘We fail people’: New data on disparities in Medicaid a...

Jun 24, 2023

Vertex’s blockbuster-in-waiting painkiller suzetrigine set for FDA review next year

Vertex’s blockbuster-in-waiting painkiller suzetrigine ...

Aug 1, 2024